secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001558370-25-001693
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure secures FDA Accelerated Approval pathway for AMT-130; 2024 net loss $239.6M
--------------------------------------------------------------------------------

- FDA agreed data from Phase I/II AMT-130 studies vs external control may support BLA; cUHDRS as intermediate endpoint, NfL as supportive.
- Cash and equivalents $367.5M at Dec 31, 2024; plus $80.7M net from public offering, funds operations into H2 2027.
- Net loss $239.6M ($4.92 loss per share) for 2024, vs $308.5M loss in 2023; revenues $27.1M up from $15.8M.
- Completed enrollment in third cohort of AMT-130 Phase I/II; initial safety update expected Q2 2025.
- Restructuring and sale of Lexington facility reduced workforce by ~65%, cut cash burn ~$70M/year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000155837025001693/0001558370-25-001693-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000155837025001693/qure-20250227x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-001693

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer